ClinicalTrials.Veeva

Menu

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Roche logo

Roche

Status

Active, not recruiting

Conditions

Breast Cancer

Treatments

Drug: Ado-trastuzumab emtamsine
Drug: Trastuzumab
Drug: Bevacizumab
Drug: Atezolizumab
Drug: Pertuzumab
Drug: Capecitabine

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT04158258
MO39485

Details and patient eligibility

About

A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.

Enrollment

2,907 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histological confirmed newly diagnosed stage I to IV (recurrent or de novo) breast cancer no more than 12 months prior to site activation, although they can have received anti-cancer treatment during that time

Exclusion criteria

  • Patients not receiving treatment for breast cancer with national approved drugs according to standard of care and in line with the current summary of product characteristics (SPC) /local labeling
  • Patients not receiving the Roche studied medicinal product, but a biosimilar

Trial design

2,907 participants in 6 patient groups

Bevacizumab
Description:
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Treatment:
Drug: Bevacizumab
Trastuzumab
Description:
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Treatment:
Drug: Trastuzumab
Ado-trastuzumab emtamsine
Description:
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Treatment:
Drug: Ado-trastuzumab emtamsine
Pertuzumab
Description:
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Treatment:
Drug: Pertuzumab
Atezolizumab
Description:
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Treatment:
Drug: Atezolizumab
Capecitabine
Description:
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Treatment:
Drug: Capecitabine

Trial contacts and locations

30

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems